Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077465 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 study of Chronic Obstructive Pulmonary Disease, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 5
- Study locations
NCT02077465: Completed Phase 1 study of Chronic Obstructive Pulmonary Disease, sponsored by Gilead Sciences.
NCT02077465 is a Phase 1 study of Chronic Obstructive Pulmonary Disease that has completed, run by Gilead Sciences. The registered enrollment target is 11 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02077465, a Phase 1 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.
Conditions Studied
Interventions
- DRUG Andecaliximab
- DRUG Placebo to match Andecaliximab
Study Locations (5)
Florida
- Advanced Pharma CR, LLC - Miami
- Elite Research Institute - Miami
- Compass Research, LLC - Orlando
New York
- University at Buffalo CTRC - Buffalo
Tennessee
- Volunteer Research Group - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-03-11 |
| Est. Completion | 2014-10-27 |
| Phase | Phase 1 |
What the finished NCT02077465 record still lists
NCT02077465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Andecaliximab is the first listed.
NCT02077465 lists 5 locations in 3 states (Florida, New York, Tennessee).
Frequently Asked Questions
What is clinical trial NCT02077465 about?
NCT02077465 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)". The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.
What is the current status of trial NCT02077465?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2014-03-11. Estimated completion is 2014-10-27.
What conditions does trial NCT02077465 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT02077465?
The interventions under investigation include: Andecaliximab (DRUG), Placebo to match Andecaliximab (DRUG).
Who is sponsoring clinical trial NCT02077465?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02077465 being conducted?
This trial has 5 study locations across Florida, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02077465's enrollment target sits among peer trials
11 84th of 86 higher than 3 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility of Semaglutide in Advanced Lung Disease
RECRUITING · Phase 1
-
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
RECRUITING · Phase 1
-
Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 1
-
Mindfulness Based Stress Reduction in COPD
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI